Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Acute on Chronic Hepatic FailureAcute Liver FailureLiver CirrhosisAcute Alcoholic Hepatitis
Interventions
DRUG

IDN-6556

OTHER

Placebo

Trial Locations (26)

10467

Montefiore Medical Center, The Bronx

20007

Georgetown University Hospital, Washington D.C.

35294

University of Alabama at Birmingham, Birmingham

39216

University of Mississippi Medical Center, Jackson

40202

Univerisity of Louisville Liver Research Center, Louisville

66160

University of Kansas Medical Center, Kansas City

84132

University of Utah, Salt Lake City

92037

Scripps Clinic, La Jolla

92161

VA San Diego Healthcare System, San Diego

94115

Sutter Pacific Medical Foundation, San Francisco

98104

University of Washington Harborview Medical Center, Seattle

SA2 8QA

Singleton Hospital, Swansea

SS16 5NL

Basildon and Thurrock University Hospital, Basildon

FY3 8NR

Blackpool Victoria Hospital, Blackpool

BS2 8HW

Bristol Royal Infirmary, Bristol

DD1 9SY

Ninewells Hospital, Dundee

Unknown

Glasgow Royal Infirmary, Glasgow

Royal London Hospital, London

Derriford Hospital, Plymouth

LE1 5WW

Leicester Royal Infirmary, Leicester

L7 8XP

Royal Liverpool University Hospital, Liverpool

NW3 2PF

University College London, Royal Free Hospital, London

M13 9WL

Central Manchester University Hospitals NHS Trust, Manchester

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

NG7 2UH

Nottingham University Hospitals NHS Trust, Nottingham

PO6 3LY

Queen Alexandra Hospital, Portsmouth

Sponsors
All Listed Sponsors
lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT01937130 - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF | Biotech Hunter | Biotech Hunter